Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial

The Lancet Oncology

Volumn 13, Issue 7, 2012, Pages 716-723

  Wang, Michael ^a   Fayad, Luis ^a   Wagner Bartak, Nicolaus ^a   Zhang, Liang ^a   Hagemeister, Fredrick ^a   Neelapu, Sattva S ^a   Samaniego, Felipe ^a   McLaughlin, Peter ^a   Fanale, Michelle ^a   Younes, Anas ^a   Cabanillas, Fernando ^b   Fowler, Nathan ^a   Newberry, Kate J ^a   Sun, Luhong ^a   Young, Ken H ^a   Champlin, Richard ^a   Kwak, Larry ^a   Feng, Lei ^a   Badillo, Maria ^a   Bejarano, Maria ^a   Hartig, Kimberly ^a   Chen, Wendy ^a   Chen, Yiming ^a   Byrne, Catriona ^c   Bell, Neda ^c   Zeldis, Jerome ^c   Romaguera, Jorge ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Hospital Auxilio Mutuo   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; TANESPIMYCIN; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ATAXIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; BLURRED VISION; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEATH; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; EYE REDNESS; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LIMB PAIN; LIVER FUNCTION; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MOOD DISORDER; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RHINORRHEA; SIDE EFFECT; STEM CELL TRANSPLANTATION; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECURRENCE; THALIDOMIDE;

EID: 84863107308     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70200-0     Document Type: Article

References (27)

1. Fernàndez V, Hartmann E, Ott G, et al. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005, 23:6364-6369.
2. Pérez-Galán P, Dreyling M, Wiestner A Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38.
3. Barista I, Romaguera JE, Cabanillas F Mantle-cell lymphoma. Lancet Oncol 2001, 2:141-148.
4. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013-7023.
5. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010, 150:200-208.
6. Wang M, Fayad L, Cabanillas F, et al. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 2008, 113:2734-2741.
7. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705-711.
8. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317-324.
9. Rubenstein JL, Treseler PA, Stewart PJ Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol 2011, 29:e595-e597.
10. Zeldis JB, Knight R, Hussein M, et al. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci 2011, 1222:76-82.
11. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009, 84:553-559.
12. Bartlett JB, Wu L, Adams M, et al. Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. Proc Am Soc Clin Oncol 2007, 25:3023.
13. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14:4650-4657.
14. Common terminology criteria for adverse events v3.0 NCI, (accessed May 23, 2012). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
16. Simon R Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
17. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
18. Nguyen DT, Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999, 62:76-82.
19. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4952-4957.
20. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377:42-51.
21. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
22. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520-525.
23. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
24. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011, 22:1622-1627.
25. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
26. Robinson KS, Williams ME, van der Jaqt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-4479.
27. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011, 12:361-368.